| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
21066 |
| Drug |
Osimertinib |
| Brand |
Tagrisso® |
| Indication |
or adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer whose tumour has epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. |
| Rapid review commissioned |
20/12/2021 |
| Rapid review completed |
13/01/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/01/2022 |
| Pre-submission consultation with Applicant |
15/03/2022 |
| Full submission received from Applicant |
16/08/2022 |
| Preliminary review sent to Applicant |
27/01/2022 |
| NCPE assessment re-commenced |
13/03/2023 |
